Chronic inflammation: A common and important factor in the pathogenesis of neoplasia

Ca-A Cancer Journal for Clinicians

Volumn 56, Issue 2, 2006, Pages 69-83

  Schottenfeld, David ^a   Beebe Dimmer, Jennifer ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GROWTH FACTOR;

ATROPHY; CANCER; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CHOLELITHIASIS; CHRONIC CHOLECYSTITIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA DAMAGE; ENTERITIS; EPSTEIN BARR VIRUS; ESOPHAGUS CANCER; GALLBLADDER CANCER; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HEPATITIS VIRUS; HUMAN; OBSTRUCTIVE AIRWAY DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; WART VIRUS;

CHRONIC DISEASE; DIGESTIVE SYSTEM DISEASES; HELICOBACTER INFECTIONS; HUMANS; INFLAMMATION; NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VIRUS DISEASES;

EID: 33645508531     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/canjclin.56.2.69     Document Type: Review

References (129)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545.
2. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
3. Dvorak HF. Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma. Am J Pathol 2003;162:1747-1757.
4. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Eng J Med 1986;315:1650-1659.
5. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875.
6. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-550.
7. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305:253-264.
8. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-483.
9. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection. Estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
10. Schottenfeld D, Beebe-Dimmer JL. Advances in cancer epidemiology: understanding causal mechanisms and the evidence for implementing interventions. Ann Rev Public Health 2005;26:37-60.
11. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
12. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
13. McGlynn KA, Tsao L, Hsing AW, et al. International trends and patterns of primary liver cancer. Int. J Cancer 2001;94:290-296.
14. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Sem Liver Dis 2003;23:125-136.
15. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-331.
16. Stern MC, Umbach DM, Yu MC, et al. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001;10:617-625.
17. Evans AA, O'Connell AP, Pugh JC, et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-565.
18. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-346.
19. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-5107.
20. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-1859.
21. Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR 2003;52:868-870.
22. Stuver SO. Towards global control of liver cancer? Sem Cancer Biol 1998;8:299-306.
23. El Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
24. Colombo M. The role of hepatitis C virus in hepatocellular carcinoma. Recent Results Cancer Res 1998;154:337-344.
25. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-919.
26. Tanaka K, Hirohata T, Koga S, et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 1991;51:2842-2847.
27. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
28. Hayashi PH, Bisceglie AM. The progression of hepatitis B- and C-infection to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Med Clin N Am 2005;89:345-369.
29. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95:1772-1783.
30. Melbye M, Frisch M. The role of human papillomaviruses in anogenital cancers. Sem Cancer Biol 1998;8:307-313.
31. Villa LL. Human papillomaviruses and cervical cancer. Adv Cancer Res 1997;71:321-341.
32. International Agency for Research on Cancer (IARC). Monographs on the evaluation of carcinogenic risk to humans: human papillomaviruses. Lyon, France: IARC Publications; 2005.
33. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002;360:228-229.
34. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer- burden and assessment of causality. J Natl Cancer Inst Monogr 2003;3-13.
35. Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br. J Cancer 2001;84:1219-1226.
36. Kjaer SK, Brinton LA. Adenocarcinomas of the uterine cervix: the epidemiology of an increasing problem. Epidemiol Rev 1993;15:486-498.
37. Lacey JV, Jr., Brinton LA, Barnes WA, et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol Oncol 2000;77:149-154.
38. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;20-28.
39. Hawes SE, Kiviat NB. Are genital infections and inflammation cofactors in the pathogenesis of invasive cervical cancer? J Natl Cancer Inst 2002;94:1592-1593.
40. Koskela P, Anttila T, Bjorge T, et al. Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer 2000;85:35-39.
41. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002;94:1604-1613.
42. Wideroff L, Schottenfeld D. Penile Cancer, in: Schottenfeld D, Fraumeni JF (eds). Cancer Epidemiology and Prevention. 3rd ed. New York: Oxford University Press; In press.
43. Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol 1999;41:911-914.
44. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
45. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Ann Rev Med 2005;56:29-44.
46. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-768.
47. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-262.
48. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 2003;22:5108-5121.
49. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003;349:1324-1332.
50. Ambinder RF, Weiss LM. Association of Epstein-Barr virus with Hodgkin's Disease, in Mauch PM, Armitage JO, Diehl V, et al (eds). Hodgkin's Disease. Philadelphia: Lippincott Williams & Wilkins; 1999:79-98.
51. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV + ve HD in young adults. Int J Cancer 2003;107:298-302.
52. Jundt F, Anagnostopoulos I, Bommert K, et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999;94:2065-2071.
53. Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma-molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11-18.
54. Enroth H, Kraaz W, Engstrand L, et al. Helicobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 2000;9:981-985.
55. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4:688-694.
56. Nyren O. Is Helicobacter pylori really the cause of gastric cancer? Sem Cancer Biol 1998;8:275-283.
57. Plummer M, Vivas J, Fauchere JL, et al. Helicobacter pylori and stomach cancer: a case-control study in Venezuela. Cancer Epidemiol Biomarkers Prev 2000;9:961-965.
58. Huang J-Q, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter Pylori seropositivity and gastric cancer. Gastroenterology 1998;114:1169-1179.
59. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283-297.
60. Aragones N, Pollan M, Rodero I, Lopez-Abente G. Gastric cancer in the European Union (1968-1992): mortality trends and cohort effect. Ann Epidemiol 1997;7:294-303.
61. Devesa SS, Blot WJ, Fraumeni JF, Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
62. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
63. Jaffe ES. Common threads of mucosa-associated lymphoid tissue lymphoma pathogenesis: from infection to translocation. J Natl Cancer Inst 2004;96:571-573.
64. Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586-594.
65. Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239-248.
66. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004;4:644-653.
67. Mahboubi E, Kmet J, Cook PJ, et al. Oesophageal cancer studies in the Caspian Littoral of Iran: the Caspian cancer registry. Br J Cancer 1973;28:197-214.
68. Saidi F, Sepehr A, Fahimi S, et al. Oesophageal cancer among the Turkomans of northeast Iran. Br J Cancer 2000;83:1249-1254.
69. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.
70. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
71. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 2003;3:676-684.
72. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-842.
73. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000;92:1316-1321.
74. Bartsch H. N-nitroso compounds and human cancer: where do we stand? IARC Sci Publ 1991;1-10.
75. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-890.
76. Lagergren J, Bergstrom R, Adami HO, Nyren O. Association between medications that relax the lower esophageal sphincter and risk for esophageal adenocarcinoma. Ann Intern Med 2000;133:165-175.
77. Laheij RJ, Straatman H, Verbeek AL, Jansen JB. Mortality trend from cancer of the gastric cardia in The Netherlands, 1969-1994. Int J Epidemiol 1999;28:391-395.
78. Craanen ME, Dekker W, Blok P, et al. Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol 1992;87:572-579.
79. El Serag HB. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin N Am 2002;31:421-440.
80. Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amindians, and Maoris. Gastroenterology 1998;115:937-946.
81. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364.
82. Tazuma S, Kajiyama G. Carcinogenesis of malignant lesions of the gall bladder. The impact of chronic inflammation and gallstones. Langenbecks Arch Surg 2001;386:224-229.
83. Csendes A, Becerra M, Rojas J, Medina E. Number and size of stones in patients with asymptomatic and symptomatic gallstones and gallbladder carcinoma: a prospective study of 592 cases. J Gastrointest Surg 2000;4:481-485.
84. Tanno S, Obara T, Fujii T, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267-275.
85. Kimura K, Ohto M, Saisho H, et al. Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258-1265.
86. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA 2005;293:330-339.
87. Chow WH, Johansen C, Gridley G. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 1999;79:640-644.
88. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004;4:695-706.
89. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000;51:289-298.
90. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 2003;24:353-362.
91. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429.
92. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94:1047-1052.
93. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-459.
94. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-862.
95. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118:671-674.
96. D'Inca R, Cardin R, Benazzato L, et al. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 2004;10:23-27.
97. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
98. Billis A, Magna LA. Inflammatory atrophy of the prostate. Prevalence and significance. Arch Pathol Lab Med 2003;127:840-844.
99. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-1992.
100. De Marzo AM, Meeker AK, Zha S, et al. Human prostate cancer precursors and pathobiology. Urology 2003;62:55-62.
101. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000;56:828-832.
102. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-S40.
103. Shah R, Mucci NR, Amin A, et al. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-1773.
104. Deutsch E, Maggiorella L, Eschwege P, et al. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol 2004;5:303-313.
105. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
106. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Ann Rev Med 2002;53:35-57.
107. Passey RD. Some problems of lung cancer. Lancet 1962;2:107-112.
108. Kuschner M. The causes of lung cancer. Am Rev Respir Dis 1968;98:573-590.
109. Prindiville SA, Byers T, Hirsch FR, et al. Sputum cytological atypia as a predictor of incident lung cancer in a cohort of heavy smokers with airflow obstruction. Cancer Epidemiol Biomarkers Prev 2003;12:987-993.
110. The Health Consequences of Smoking: Chronic Obstructive Lung Disease. A Report of the Surgeon General. DHHS Pub No. 84-50205. Washington, DC: US Department of Health and Human Services, Office of Smoking and Health; 1984.
111. Hinds MW, Cohen HI, Kolonel LN. Tuberculosis and lung cancer risk in nonsmoking women. Am Rev Respir Dis 1982;125:776-778.
112. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996;313:711-715.
113. Islam SS, Schottenfeld D. Declining FEV1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. Cancer Epidemiol Biomarkers Prev 1994;3:289-298.
114. Kuller LH, Ockene J, Meilahn E, Svendsen KH. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Epidemiol 1990;132:265-274.
115. Lange P, Nyboe J, Appleyard M, et al. Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer. Am Rev Respir Dis 1990;141:613-617.
116. Santillan AA, Camargo CA, Jr., Colditz GA. A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control 2003;14:327-334.
117. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512-518.
118. Zheng W, Blot WJ, Liao ML, et al. Lung cancer and prior tuberculosis infection in Shanghai. Br J Cancer 1987;56:501-504.
119. Wanner A, Salathe M, O'Riordan TG. Mucociliary clearance in the airways. Am J Respir Crit Care Med 1996;154:1868-1902.
120. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 2005;352:1967-1976.
121. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997;89:857-862.
122. Aoyagi Y, Yokose T, Minami Y, et al. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res 2001;61:7950-7954.
123. Carbone DP, Minna JD. The molecular genetics of lung cancer. Adv Intern Med 1992;37:153-171.
124. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Ann Rev Med 2003;54:73-87.
125. Ryrfeldt A, Bannenberg G, Moldeus P. Free radicals and lung disease. Br Med Bull 1993;49:588-603.
126. Husain AN, Kumar V. The Lung, in Kumar V, Abbas AK, Fausto N (eds). Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia: Elsevier Saunders; 2005:728-737.
127. Weil H, McDonald JC. Exposure to crystalline silica and risk of lung cancer: the epidemiologic evidence. Thorax 1996;51:97-102.
128. Kamp DW, Weitzman SA. Asbestosis: clinical spectrum and pathogenic mechanisms. Proc Soc Exp Biol Med 1997;214:12-26.
129. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.